

# Scalability of novel therapies

Wednesday, November 23, 2022  
uniQure, Amsterdam

Organized by the Dutch Biotechnological Society (NBV)  
Biopharma working group

*This session is chaired by Lenneke de Winter and Michel Eppink.*

## Program

- 18:00 Registration, Coffee & Sandwiches
- 18:30 Opening by Session Chairs
- 18:35 Applying the AdVac® platform to development of a COVID-19 vaccine  
*Marcel de Vocht*  
*Scientific Director Process Development | Janssen Vaccines*
- 19:05 Virus-like particle vaccines from insect cells: Development of a COVID-19 vaccine  
*Jort Altenburg*  
*PhD candidate | Wageningen University*
- 19:35 Break
- 20:00 High-throughput scale-down model for fast USP development in gene therapy  
*Hugo Rojas*  
*USP Lead Scientist | uniQure*
- 20:30 Closing & Drinks
- 22:00 End

**Registration: [click here](#)**

*Free for NBV members  
€30 for non-members*



## Applying the AdVac® platform to development of a COVID-19 vaccine Marcel de Vocht | Janssen Vaccines



The AdVac® platform, which comprises an Adenovirus vector being produced by means of our proprietary cell line, was applied for development of a COVID-19 vaccine candidate. Prior knowledge on the production process and close interaction with the regulatory authorities on the submission strategies were key elements for acceleration of the vaccine development and preparation of the market authorization application. In parallel to the process and clinical development, the process was transferred to several internal and external manufacturing sites, which, in one case, required major reconstruction of the facility. It will be presented how all these elements came together to enable rapid manufacturing of a large vaccine supply to combat COVID-19.

## Virus-like particle vaccines from insect cells: Development of a COVID-19 vaccine

Jort Altenburg | Wageningen University



To control the pandemic SARS-CoV-2 outbreak, rapid development of a COVID-19 vaccine was needed. As part of the Prevent-nCoV consortium, we utilized in-house knowledge on the baculovirus-insect cell expression system to develop an experimental VLP nanoparticle vaccine against SARS-CoV-2. I will present preclinical data, discuss the scalability of our systems and describe the process development. In addition I will discuss using methods such as online monitoring and screening microbioreactors to increase our understanding of the process.



## High-throughput scale-down model for fast USP development in gene therapy

Hugo Rojas | uniQure

The necessity to minimize the timeline to develop commercial cell culture processes have opened up opportunities for implementing high-throughput technologies. In this talk we aim at discussing challenges and opportunities to accelerate process development of AAV-gene therapies by leveraging concepts of scale down models and high-throughput experimentation. Particularly, we will focus on efforts of scaling-down our manufacturing process into an ambr250 system and its implications



## Closing and Drinks

When time is up, the discussion can be continued over drinks until **22:00**.

## Directions and parking

### Address

**Paasheuvelweg 25a  
1105BP  
Amsterdam**

### Public transport

Metro/train  
Holendrecht

*5 minute walk*

### Parking

ParkBee  
Pietersbergweg 53  
Amsterdam

*€2/hour*

## Registration: click [here](#)

*Free for NBV members  
€30 for non-members*

